Trade-Ideas LLC identified

Chimerix

(

CMRX

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Chimerix as such a stock due to the following factors:

  • CMRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $21.6 million.
  • CMRX traded 342,144 shares today in the pre-market hours as of 8:40 AM, representing 11.2% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CMRX with the Ticky from Trade-Ideas. See the FREE profile for CMRX NOW at Trade-Ideas

More details on CMRX:

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. Currently there are 8 analysts that rate Chimerix a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Chimerix has been 356,600 shares per day over the past 30 days. Chimerix has a market cap of $1.6 billion and is part of the health care sector and drugs industry. The stock has a beta of -0.18 and a short float of 8.6% with 0.89 days to cover. Shares are down 11.7% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Chimerix as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

Highlights from the ratings report include:

  • CMRX's very impressive revenue growth greatly exceeded the industry average of 13.4%. Since the same quarter one year prior, revenues leaped by 91.6%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • CMRX's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 10.50, which clearly demonstrates the ability to cover short-term cash needs.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Biotechnology industry and the overall market, CHIMERIX INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$24.93 million or 117.74% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.